Anda belum login :: 19 Apr 2025 06:25 WIB
Home
|
Logon
Hidden
»
Administration
»
Collection Detail
Detail
Folic acid supplementation lowers blood arsenic
Oleh:
Gamble, Mary V.
;
Xinhua, Liu
;
Slavkovich, Vesna
;
Pilsner, J. Richard
;
Ilievski, Vesna
;
Factor-Litvak, Pam
;
Levy, Diane
;
and Others
Jenis:
Article from Journal - ilmiah internasional
Dalam koleksi:
The American Journal of Clinical Nutrition vol. 86 no. 04 (Oct. 2007)
,
page 1202.
Topik:
Folic acid
;
folate deficiency
;
homocysteine
;
S-adenosylmethionine
;
SAM
;
creatinine
;
arsenic
;
monomethylarsonic acid
;
dimethylarsinic acid
;
blood arsenic
Ketersediaan
Perpustakaan FK
Nomor Panggil:
A07.K.2007.04
Non-tandon:
1 (dapat dipinjam: 0)
Tandon:
tidak ada
Lihat Detail Induk
Isi artikel
Background: Chronic arsenic exposure currently affects >100 million persons worldwide. Methylation of ingested inorganic arsenic (InAs) to monomethylarsonic (MMAs) and dimethylarsinic (DMAs) acids relies on folate-dependent one-carbon metabolism and facilitates urinary arsenic elimination. Objective: We hypothesized that folic acid supplementation to arsenic-exposed Bangladeshi adults would increase arsenic methylation and thereby lower total blood arsenic. Design: In this randomized, double-blind, placebo-controlled trial, we evaluated blood concentrations of total arsenic, InAs, MMAs, and DMAs in 130 participants with low plasma folate (<9 nmol/L) before and after 12 wk of supplementation with folic acid (400 µg/d) or placebo. Results: MMAs in blood was reduced by a mean ± SE of 22.24 ± 2.86% in the folic acid supplementation group and by 1.24 ± 3.59% in the placebe group (P < 0.0001). There was no change in DMAs in blood; DMAs is rapidly excreted in urine as evidenced by an increase in urinary DMAs (P = 0.0099). Total blood arsenic was reduced by 13.62% in the folic acid supplementation group and by 2.49% in the placebo group (P = 0.0199). Conclusions: Folic acid supplementation to participants with low plasma concentrations of folate lowered blood arsenic concentrations, primarily by decreasing blood MMAs and increasing urinary DMAs. Therapeutic strategies to facilitate arsenic methylation, particularly in populations with folate deficiency or hyperhomocysteinemia or both, may lower blood arsenic concentrations and thereby contribute to the prevention of arsenic-induced illnesses.
Opini Anda
Klik untuk menuliskan opini Anda tentang koleksi ini!
Kembali
Process time: 0.015625 second(s)